DELCATH SYSTEMS, INC. (DCTH) stock intrinsic value fair value estimate & owner earnings analysis

Delcath makes HEPZATO KIT, a system that isolates the liver's blood supply so a high dose of the chemotherapy drug melphalan can be pumped straight into liver tumours and filtered out before it reaches the rest of the body. The FDA approved it in August 2023 for liver-dominant metastatic uveal melanoma, a rare eye cancer that spreads to the liver; a European version, CHEMOSAT, has been sold for longer. HEPZATO is the only approved treatment for the roughly 55% of these patients who cannot receive Immunocore's KIMMTRAK. Revenue went from $2.1 million in 2023 to $37.2 million in 2024 and $85.2 million in 2025 ($78.8 million HEPZATO, $6.4 million CHEMOSAT), with 24 US centers treating patients in 2025 against 14 a year earlier. The first half of 2026 brought $54.1 million of revenue, up 23%, and the second quarter alone was $29.1 million. What the business earns for owners. We start from operating cash flow, strip out the timing effect of working capital, and charge stock compensation as the real cost it is, because Delcath pays a large part of its staff in shares. In 2025 the business generated $25.6 million of cash before working-capital swings, but stock compensation was $24.2 million, and maintenance spending on equipment was about $0.6 million. That leaves owner earnings of about $0.8 million, or 2 cents a share: the first positive year in the company's history, after losses of $35 million in 2022, $39 million in 2023 and $13 million in 2024. Every earlier year described a company that was still trying to get approved, so it tells us nothing about the earning power of today's business. That leaves one barely positive year and two quarters, which is far too little to set a normal earnings level with any confidence. Our previous figures understated 2025 slightly because they did not separate out working-capital movements; the business has not changed for that reason. How we built the cases. We credit only revenue the company has already reached. No further growth is assumed in any case, because expansion to more centers, more patients per center and new indications have not happened yet. The second-quarter 2026 revenue rate of about $116 million a year is the starting level. Gross margin runs about 86-88%. The big swing item is the cost structure: selling and administration of about $52 million and research of about $29 million in 2025, now rising as the company runs Phase 2 trials in colorectal and breast cancer liver metastases. We treat those trials as optional spending that ends once they read out, not as a source of value, since no result exists yet. Delcath has about $101 million of usable federal tax losses (another $195 million will expire unused because of past ownership changes), so it pays little federal tax for several years. Orphan exclusivity for the uveal melanoma indication runs seven years from the 2023 approval, to about 2030, and the device is protected by 13 US utility patents plus trade secrets in manufacturing the filter and catheter. Base case: revenue holds at about $116 million and costs stay near today's level while the trials run through 2028, so the business throws off only $5-7 million a year after stock compensation. Once the trial spending ends, research falls back toward $22 million and owner earnings settle around $24 million a year. Exclusivity lapses around 2030, and IDEAYA's darovasertib combination and Replimune's RP2 are already in registration-stage trials in the same disease. On that evidence we assume the franchise holds through about 2036 and then fades to nothing by 2040 instead of running forever, because nothing proven yet replaces it. The business is worth about $143 million. Delcath has no debt and held $95.9 million of cash and short-term investments at June 30, 2026. Setting aside about $10 million for day-to-day needs, the shares are worth about $229 million, or $5.75 each on 39.8 million diluted shares. The diluted count includes the Series E and F convertible preferred, which convert into common stock at $3.30-$10.00 a share. Bear case: this is a one-product, one-indication business with a hospital customer base and a competitor pipeline, and that is the risk we model. Revenue holds near $110 million through 2028 while trial spending absorbs almost all the cash. In 2030 orphan exclusivity ends and a newly approved drug from the current pipeline takes share, so revenue falls toward $72 million, the business runs at a small loss after stock compensation, and we assume management cuts the business back by 2033 rather than burning the cash. The operating business is worth roughly nothing, and the shares are worth roughly the cash, about $2.16. The case does not include a product recall or a safety-driven label change. These have not happened, but they are the outcomes most likely to be worse than this case. Bull case: centers already treating patients keep growing usage as they did in 2025, revenue reaches about $150 million by 2028, and once trial spending ends owner earnings reach about $47 million a year and fade from 2036 to 2042. The business is worth about $302 million, or $9.74 a share with the cash. A positive colorectal or breast cancer trial would add value beyond this, but that is not in hand and is not counted. Margin-of-safety price. We are not confident in the earnings level. There is one barely positive year, stock compensation is as large as operating cash flow, and the whole business depends on one product in one rare cancer, sold to a few dozen hospitals; one customer was 15% of 2025 revenue. If the next registration-stage drug in uveal melanoma succeeds around 2029-2030, much of this business could go away. The balance sheet provides protection: no debt and about $2.40 a share of cash and investments, partly shrunk by a $25 million buyback authorised in November 2025. If we are wrong about cost discipline or about competition, the shares are worth about the cash. If we are wrong in the other direction, they are worth $8-10. The price assumes a three-to-four-year holding period, through the trial readouts and the 2030 exclusivity date, with no dividend while waiting. At $3.00 the price is about 60 cents a share beyond the cash for a business already selling at a $116 million annual rate. If the base case plays out, from $3.00 it implies about 20% a year toward $5.75 over roughly 3.5 years, and the bear case implies a decline of about 28% if the business proves worth only its cash. That is the highest price at which we think the odds support a 20% return.